Carisma Therapeutics 4/1/2024 Earnings Report

Carisma Therapeutics EPS Results

• Actual EPS: -$0.52
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Carisma Therapeutics Revenue Results

• Actual Revenue: $4.29 million
• Expected Revenue: $4.00 million
• Beat/Miss: Beat by +$290.00 thousand
• YoY Revenue Growth: N/A

Carisma Therapeutics Announcement Details

• Date: 4/1/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Carisma Therapeutics (NASDAQ:CARM), Inc. is a clinical-stage biotechnology company headquartered in the United States that focuses on harnessing the innate immune system to treat cancer and inflammatory diseases. Through its proprietary CARMA (Chimeric Antigen Receptor Macrophage) platform, Carisma engineers macrophages and other myeloid cells to seek out, engulf and destroy diseased cells while reprogramming the surrounding microenvironment. This approach aims to address key limitations of existing T-cell therapies by leveraging the unique trafficking and immunomodulatory properties of innate immune cells.

The company’s lead oncology candidate, CT-0508, employs a HER2-targeted CAR expressed on macrophages to infiltrate and remodel HER2-positive solid tumors. In parallel, Carisma is advancing CT-381, an engineered myeloid cell therapy designed to modulate inflammatory and autoimmune conditions. Preclinical data have demonstrated robust antigen-dependent activation, tumor penetration and anti-tumor efficacy in multiple models, supporting the progression of these programs toward their first clinical studies.

Carisma’s interdisciplinary team combines expertise in myeloid biology, genetic engineering and translational medicine. The company partners with leading academic institutions and specialized contract development and manufacturing organizations to establish scalable, GMP-compliant processes for its cell therapies. By uniting macrophage biology with CAR engineering, Carisma Therapeutics seeks to create a novel class of treatments with broad applications across oncology and immune-mediated diseases.